Cytoskeletal association of human alpha-interferon-receptor complexes in interferon-sensitive and -resistant lymphoblastoid cells - PubMed (original) (raw)
Cytoskeletal association of human alpha-interferon-receptor complexes in interferon-sensitive and -resistant lymphoblastoid cells
L M Pfeffer et al. Proc Natl Acad Sci U S A. 1987 May.
Abstract
Human Daudi lymphoblastoid cells, which are highly sensitive to the antiproliferative action of human leukocyte alpha-interferon (IFN-alpha), and IFN-resistant and IFN-sensitive Daudi subclones (Cl2 and Cl1, respectively), contain 2300 (Kd = 20 X 10(-12) M), 3000 (Kd = 45 X 10(-12) M), and 3700 (Kd = 52 X 10(-12) M) IFN-alpha binding sites per cell, respectively. Thus, these IFN-sensitive and IFN-resistant cells have similar numbers of high-affinity IFN-alpha receptors. IFN-receptor complexes that are insoluble in Triton X-100 accumulate in IFN-sensitive but not in IFN-resistant cells. The ligand-induced accumulation of Triton-insoluble complexes in IFN-sensitive cells was inhibited by cytochalasin B. This suggests that the solubility change of IFN-receptor complexes results from their interaction with the cytoskeletal matrix. The dissociation of IFN-alpha from IFN-sensitive and IFN-resistant cells can be resolved into fast and slow components. IFN-alpha dissociates more slowly from IFN-sensitive cells than from IFN-resistant cells. Very slow dissociation of IFN-alpha from Triton-insoluble complexes correlates with this difference. These observations suggest that IFN-receptor complexes become coupled to the cytoskeletal matrix in IFN-sensitive but not in IFN-resistant cells, and that such interaction is an important element in the mechanism of the antiproliferative action of IFN-alpha on Daudi cells.
Similar articles
- Comparative antiproliferative and receptor binding activities of interferons alpha and beta on lymphoblastoid and melanoma cells.
Hertzog PJ, Johns TG, Callister KA, Dinatale A, Linnane AW. Hertzog PJ, et al. Biochem Int. 1990 Dec;22(6):1095-102. Biochem Int. 1990. PMID: 2151021
Cited by
- Anti-metastatic functions of type 1 interferons: Foundation for the adjuvant therapy of cancer.
Ortiz A, Fuchs SY. Ortiz A, et al. Cytokine. 2017 Jan;89:4-11. doi: 10.1016/j.cyto.2016.01.010. Epub 2016 Jan 25. Cytokine. 2017. PMID: 26822709 Free PMC article. Review. - Multifarious determinants of cytokine receptor signaling specificity.
Moraga I, Spangler J, Mendoza JL, Garcia KC. Moraga I, et al. Adv Immunol. 2014;121:1-39. doi: 10.1016/B978-0-12-800100-4.00001-5. Adv Immunol. 2014. PMID: 24388212 Free PMC article. Review. - Ligand-independent interaction of the type I interferon receptor complex is necessary to observe its biological activity.
Krause CD, Digioia G, Izotova LS, Xie J, Kim Y, Schwartz BJ, Mirochnitchenko OV, Pestka S. Krause CD, et al. Cytokine. 2013 Oct;64(1):286-97. doi: 10.1016/j.cyto.2013.06.309. Epub 2013 Jul 3. Cytokine. 2013. PMID: 23830819 Free PMC article. - The Epstein-Barr virus-encoded LMP-1 oncoprotein negatively affects Tyk2 phosphorylation and interferon signaling in human B cells.
Geiger TR, Martin JM. Geiger TR, et al. J Virol. 2006 Dec;80(23):11638-50. doi: 10.1128/JVI.01570-06. Epub 2006 Sep 20. J Virol. 2006. PMID: 16987978 Free PMC article. - Globotriaosyl ceramide modulates interferon-alpha-induced growth inhibition and CD19 expression in Burkitt's lymphoma cells.
Maloney MD, Binnington-Boyd B, Lingwood CA. Maloney MD, et al. Glycoconj J. 1999 Dec;16(12):821-8. doi: 10.1023/a:1007145420116. Glycoconj J. 1999. PMID: 11133022
References
- J Gen Virol. 1975 Aug;28(2):207-17 - PubMed
- Proc Soc Exp Biol Med. 1976 Dec;153(3):501-4 - PubMed
- J Biol Chem. 1979 May 10;254(9):3315-25 - PubMed
- Cell. 1979 Aug;17(4):859-65 - PubMed
- Int J Cancer. 1979 Sep 15;24(3):314-8 - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources